Visiting Professor of Hepatology
Radcliffe Department of Medicine
University of Oxford
Oxford, United Kingdom
Stephen A. Harrison, MD, COL (Ret.), FAASLD, has disclosed that he has received consulting fees from Bristol-Myers Squibb, the Chronic Liver Disease Foundation, FibroGen, Genfit, Intercept, Medivation, Merck, NGM Biopharmaceuticals, and Pfizer; has received fees for non-CME/CE services from AbbVie, Alexion, Gilead Sciences, and Merck; and funds for research support paid to his institution from Bristol-Myers Squibb, Conatus, Galectin, Galmed, Gilead Sciences, Immuron, Intercept, Madrigal, Merck, NGM Biopharmaceuticals, and Tobira.
Professor of Experimental Hepatology
Institute of Cellular Medicine
Newcastle Upon Tyne, United Kingdom
Quentin M. Anstee, BSc, MB BS, PhD, MRCP(UK), FRCP, has disclosed that he has received consulting fees paid to his institution from Acuitas Medical, Genfit, Intercept, Inventiva, Janssen, Lilly, NewGene, Pfizer, Raptor Pharmaceuticals, and Tobira and funds for research support paid to his institution from AbbVie and GlaxoSmithKline.
Associate Professor of Medicine
Feinberg School of Medicine
Mary E. Rinella, MD, has disclosed that she has received consulting fees from Amarin, BioPharma, Echosens, Enanta, Immuron, Intercept, NGM Biopharmaceuticals, and NuSirt.
Adult Nurse Practitioner
Division of Medicine, Hepatology
Weill Cornell Medical College
New York, New York
Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.
Manager, Editorial Operations
Kiran D. Mir-Hudgeons, PhD, has no real or apparent conflicts of interest to report.
Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.
Director, Scientific Services
Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.
Zachary Schwartz, MSc, ELS, has no real or apparent conflicts of interest to report.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This program is intended for physicians and other healthcare providers involved in the care of patients with NASH.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 2.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 23, 2016, through December 22, 2017:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
CCO slides from Martin Abrahamson, MD, and Anne Peters, MD, on GLP-1 RAs to address elevated A1C, obesity, and CV risk, plus strategies to improve tolerability, adherence
Slides from CCO and John Russell, MD, on GLP-1 RAs to address elevated A1C, obesity, and CV risk, plus strategies to improve tolerability, adherence
CME: Type 2 diabetes management: Dr. Veronica K. Piziak on NPH, regular insulin, switching to avoid hypoglycemia/reduce CV risk in T2DM
Dr. Kenneth Cusi summarizes some of the most important data from recent studies in patients at high risk for NASH/NAFLD.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.